Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC) Meeting Abstract
| Authors: | Tran, B.; Horvath, L.; Dorff, T. B.; Greil, R.; Machiels, J. P. H.; Roncolato, F.; Autio, K. A.; Rettig, M.; Fizazi, K.; Lolkema, M. P.; Fermin, A. C.; Salvati, M.; Kouros-Mehr, H. |
| Abstract Title: | Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC) |
| Meeting Title: | 2020 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2020 Feb 13-15 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-02-20 |
| Language: | English |
| ACCESSION: | WOS:000529525900014 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.6_suppl.TPS261 |
| Notes: | Meeting Abstract: TPS261 -- Source: Wos |
